K-5a2

Cat. No.: HY-173427: Data Sheet Handling Instructions
FAQs
Technical Support

K-5a2 is the non-isotopic form of ZK-316 (HY-173427S). ZK-316 is a potent and broad-spectrum NNRTI inhibitor with an EC₅₀ value ranging from 0.99 to 75.1 nM. ZK-316 can be used in the study of HIV.

For research use only. We do not sell to patients.

K-5a2 Chemical Structure

CAS No. : 1810730-10-9

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of K-5a2:

ZK-316 Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	0.13 μM Compound: 3; K-5a2	Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay	[PMID: 31935327]
HEK293	IC₅₀	0.13 μM Compound: 3; K-5a2	Inhibition of human ERG expressed in HEK293 cells by whole cell electrophysiology assay Inhibition of human ERG expressed in HEK293 cells by whole cell electrophysiology assay	[PMID: 32293182]
MT4	CC₅₀	> 227 μM Compound: K-5a2	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 32200201]
MT4	CC₅₀	> 227890 nM Compound: 27	Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	1.4 nM Compound: 27	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	2.9 nM Compound: 27	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	2.9 nM Compound: 27	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	3 nM Compound: 27	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	3.2 nM Compound: 27	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	3.4 nM Compound: 27	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	4.2 nM Compound: 27	Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	>= 227890 nM Compound: 27	Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
TZM	CC₅₀	> 227 nM Compound: 3; K-5a2	Cytotoxicity against human TZM-bl cells after 4 days by XTT assay Cytotoxicity against human TZM-bl cells after 4 days by XTT assay	[PMID: 30624934]

Molecular Weight

548.68

Formula

C₂₇H₂₈N₆O₃S₂

CAS No.

1810730-10-9

SMILES

N#CC1=CC(C)=C(OC2=C3SC=CC3=NC(NC4CCN(CC4)CC5=CC=C(C=C5)S(=O)(N)=O)=N2)C(C)=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Zhang K, et al. Deuteration Strategy-Inspired Design of Novel Diarylpyrimidine Derivatives as Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Improved Efficacy, Selectivity, and Druggability. J Med Chem. 2025 Apr 24;68(8):8564-8577. [Content Brief]

K-5a2 Related Classifications

Infection

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

K-5a21810730-10-9Reverse TranscriptaseHIVHuman immunodeficiency virusNNRTIInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *